查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917824

用于治疗睡眠呼吸中止症的居家医疗设备 - 2026-2031 年预测

Home-Based Sleep Apnea Devices Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2025 年，睡眠呼吸中止症居家医疗设备市场规模将达到 23.99 亿美元，到 2031 年将达到 56.47 亿美元，复合年增长率为 15.34%。

睡眠呼吸中止症居家医疗设备市场涵盖了用于诊断和治疗睡眠相关呼吸障碍（主要是阻塞型睡眠呼吸中止症(OSA)）的医疗设备的研发、生产和销售，这些设备无需在传统睡眠检查室即可使用。此细分市场包含多种技术，从诊断筛检工具到用于正压通气 (PAP) 治疗的设备。这些解决方案利用先进的传感器、数据分析和以用户为中心的设计，为家庭用户提供了便捷、易用且临床有效的替代方案，以取代中心多导睡眠图检查，从而解决睡眠障碍识别和管理长期护理方面的关键挑战。

市场扩张的根本驱动力在于流行病学、技术和医疗服务趋势的强大联合。其中一个关键催化剂是全球睡眠呼吸中止症盛行率的不断上升，而这又受到人口老化、肥胖率上升以及临床医生日益认识到睡眠呼吸中止症与心血管疾病、糖尿病和认知障碍之间关联的推动。病患群体的快速成长对有限的睡眠检查室资源造成了不可持续的需求，因此亟需可扩展的诊断替代方案。同时，远端医疗和远端患者监护（RPM）模式的普及，得益于近期医疗服务模式的转变，为分散式睡眠照护创造了有利环境。这些模式依赖可靠的居家数据收集，居家睡眠呼吸中止症检测（HSAT）和连网治疗设备已成为虚拟护理路径的重要组成部分。

一项关键的技术趋势是诊断和监测设备正朝着更精密、小型化和使用者友善的方向快速发展。最新的 III 型和 IV 型家用睡眠测试设备将多种感测器（测量气流、呼吸努力、脉搏血氧计，在某些情况下还能测量打鼾和体位）整合到一种不显眼的可穿戴设备中。这种向非侵入式、舒适设备的转变对于提高患者对测试通讯协定的依从性以及确保数据准确性至关重要。此外，透过蓝牙或蜂窝网路连接与数位健康平台集成，可实现数据无缝传输到云端门户，供临床医生查看，并有助于实现自动评分演算法。配套应用程式也支持病人参与，从而为治疗管理创建持续的回馈循环。

从地理来看，北美是市场最为成熟发达，其特点是疾病认知度高，家庭睡眠呼吸中止症检测（HSAT）和持续气道正压通气（PAP）的报销机製完善，且主要设备製造商集中于此。该地区的法规环境和支付方政策历来对家庭检测持支持态度，巩固了其作为创新、临床检验和商业化策略中心的重要地位。

儘管成长要素强劲，但市场在临床检验、报销和患者依从性方面仍面临诸多挑战。确保家用诊断设备的正确使用始终是一个难题。这些设备通常会推荐给患有中重度阻塞性睡眠呼吸中止症（OSA）且无明显合併症的患者。使用不当可能导致假阴性结果和评估不足。家用检测和监测的报销政策仍在不断发展变化，且因地区而异，这影响着市场进入和商业性可行性。长期患者依从性是整个治疗设备产业（尤其是PAP设备）面临的关键挑战，这推动了设备舒适度（例如面罩设计、压力释放技术）和数位指导工具的创新，以提高患者的依从性。

呼吸和睡眠医学领域的竞争格局主导由全球领先领导企业，它们凭藉包括诊断设备、PAP呼吸器、面罩和数位健康平台在内的全面产品系列竞争。竞争的重点在于感测器精度、数据整合能力和患者介面系统舒适度等方面的技术差异化，以及建构连接患者、医疗服务提供者和支付方的综合数位生态系统。成功与否取决于能否证明其产品能够改善患者预后并提高成本效益，贯穿从诊断到长期治疗管理的整个医疗服务链。

总之，睡眠呼吸中止症居家医疗设备市场是向去中心化、以患者为中心的远端医疗。对于业内专家而言，策略重点应集中在以下三点：透过提高更简便设备的诊断准确性来扩大其合理使用范围；开发无缝连接诊断、治疗启动和依从性支持的整合数位化路径；以及产生可靠的真实世界证据，以确保获得有利且稳定的报销。成功取决于创建端到端的解决方案，这些方案不仅能够识别疾病，还能有效地引导患者进行长期管理，从而改善临床结果并减轻未治疗睡眠呼吸中止症对整个医疗系统的负担。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 依设备类型分類的睡眠呼吸中止症居家医疗器材市场

  • 介绍
  • 正压通气（PAP）设备
    • 持续正压呼吸器
    • 自调节正压呼吸装置
    • 双水平正压呼吸装置
  • 口内矫正器
  • 其他的

6. 依睡眠呼吸中止症类型分類的居家医疗设备市场

  • 介绍
  • 阻塞型睡眠呼吸中止症症（OSA）
  • 中枢性睡眠呼吸中止症（CSA）

7. 按最终用户分類的睡眠呼吸中止症居家医疗器材市场

  • 介绍
  • 儿童（18岁以下）
  • 成年人（18-65岁）
  • 老年人（65岁以上）

8. 各地区睡眠呼吸中止症居家医疗器材市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章：竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • ResMed Inc.
  • Koninklijke Philips NV
  • Fisher & Paykel Healthcare Limited
  • Drive DeVilbiss Healthcare
  • BMC Medical Co., Ltd
  • Compumedics Limited
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • SomnoMed Limited
  • Somnetics, International Inc.

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615809

Home-Based Sleep Apnea Devices Market, with a 15.34% CAGR, is expected to grow to USD 5.647 billion in 2031 from USD 2.399 billion in 2025.

The home-based sleep apnea devices market encompasses the development, manufacturing, and distribution of medical devices designed for the diagnosis and management of sleep-related breathing disorders, primarily obstructive sleep apnea (OSA), outside of traditional sleep laboratories. This market segment includes a spectrum of technologies ranging from diagnostic screening tools to therapeutic devices for positive airway pressure (PAP) therapy. These solutions leverage advanced sensors, data analytics, and user-centric design to provide accessible, convenient, and clinically valid alternatives to in-lab polysomnography, addressing critical gaps in sleep disorder identification and long-term care management.

Market expansion is fundamentally driven by a powerful confluence of epidemiological, technological, and healthcare delivery trends. The primary catalyst is the globally rising prevalence of sleep apnea, fueled by aging demographics, increasing rates of obesity, and greater clinical recognition of the condition's association with cardiovascular disease, diabetes, and cognitive impairment. This burgeoning patient population creates an unsustainable demand for limited sleep lab resources, necessitating scalable diagnostic alternatives. Concurrently, the accelerated adoption of telemedicine and remote patient monitoring (RPM) models, accelerated by recent shifts in healthcare delivery, has created a receptive ecosystem for decentralized sleep care. These models rely on reliable home-based data collection, making home sleep apnea tests (HSATs) and connected therapeutic devices integral components of virtual care pathways.

A dominant technological trend is the rapid evolution of diagnostic and monitoring devices toward greater sophistication, miniaturization, and user-friendliness. Modern Type III and IV home sleep tests incorporate multi-parameter sensors-measuring airflow, respiratory effort, pulse oximetry, and sometimes snoring or body position-packaged into unobtrusive, wearable formats. This shift towards non-intrusive, comfortable devices is critical for improving patient compliance with testing protocols and ensuring data accuracy. Furthermore, integration with digital health platforms via Bluetooth or cellular connectivity enables seamless data transmission to cloud-based portals for clinician review, facilitates automated scoring algorithms, and supports patient engagement through companion apps, creating a continuous feedback loop for therapy management.

Geographically, North America remains the most mature and advanced market, characterized by high disease awareness, established reimbursement frameworks for HSATs and PAP therapy, and a concentration of leading device manufacturers. The region's regulatory environment and payer policies have historically been more adaptive to home-based testing, solidifying its role as the primary center for innovation, clinical validation, and commercial strategy.

Despite strong growth drivers, the market navigates significant challenges related to clinical validation, reimbursement, and patient adherence. A persistent challenge is ensuring the appropriate use of home-based diagnostic devices, which are generally recommended for patients with a high pre-test probability of moderate to severe OSA and without significant comorbidities. Misapplication can lead to false negatives or inadequate assessment. Reimbursement policies for home-based testing and monitoring continue to evolve and vary by region, impacting market access and commercial viability. For therapeutic devices, particularly PAP machines, long-term patient adherence remains a critical industry-wide hurdle, driving innovation in device comfort (e.g., mask design, pressure relief technology) and digital coaching tools to improve compliance.

The competitive landscape is dominated by established global leaders in respiratory and sleep medicine, who compete across a full portfolio of diagnostic devices, PAP machines, masks, and digital health platforms. Competition centers on technological differentiation in sensor accuracy, data integration capabilities, patient interface comfort, and the development of comprehensive digital ecosystems that connect patients, providers, and payers. Success hinges on demonstrating improved patient outcomes and cost-effectiveness across the care continuum, from diagnosis to long-term therapy management.

In conclusion, the home-based sleep apnea devices market is a dynamic and essential component of the shift towards decentralized, patient-centric healthcare. Its growth is structurally supported by the high and growing burden of sleep apnea and the irreversible trend toward telehealth. For industry experts, strategic focus must center on advancing the diagnostic accuracy of simpler devices to expand their appropriate use, developing integrated digital pathways that seamlessly connect diagnosis with treatment initiation and adherence support, and generating robust real-world evidence to secure favorable and stable reimbursement. Success depends on creating end-to-end solutions that not only identify the disease but also effectively engage patients in long-term management, thereby improving clinical outcomes and reducing the overall systemic burden of untreated sleep apnea.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Home-Based Sleep Apnea Market Segmentation

  • By Device Type
  • Positive Airway Pressure (PAP) Device
  • Continuous Positive Airway Pressure Device
  • Auto-Adjusting Positive Airway Pressure Device
  • Bilevel Positive Airway Pressure Device
  • Oral Appliance
  • Others
  • By Sleep Apnea Type
  • Obstructive Sleep Apnea (OSA)
  • Central Sleep Apnea (CSA)
  • By End-User
  • Pediatric (Under 18 Years)
  • Adults (18 To 65 Years)
  • Old-Age (Above 65 Years)
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HOME-BASED SLEEP APNEA MARKET BY DEVICE TYPE

  • 5.1. Introduction
  • 5.2. Positive Airway Pressure (PAP) Device
    • 5.2.1. Continuous Positive Airway Pressure Device
    • 5.2.2. Auto-Adjusting Positive Airway Pressure Device
    • 5.2.3. Bilevel Positive Airway Pressure Device
  • 5.3. Oral Appliance
  • 5.4. Others

6. HOME-BASED SLEEP APNEA MARKET BY SLEEP APNEA TYPE

  • 6.1. Introduction
  • 6.2. Obstructive Sleep Apnea (OSA)
  • 6.3. Central Sleep Apnea (CSA)

7. HOME-BASED SLEEP APNEA MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pediatric (Under 18 Years)
  • 7.3. Adults (18 To 65 Years)
  • 7.4. Old-Age (Above 65 Years)

8. HOME-BASED SLEEP APNEA MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Italy
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. ResMed Inc.
  • 10.2. Koninklijke Philips N.V
  • 10.3. Fisher & Paykel Healthcare Limited
  • 10.4. Drive DeVilbiss Healthcare
  • 10.5. BMC Medical Co., Ltd
  • 10.6. Compumedics Limited
  • 10.7. Natus Medical Incorporated
  • 10.8. Nihon Kohden Corporation
  • 10.9. SomnoMed Limited
  • 10.10. Somnetics, International Inc.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations